Evidence map›Paper›PMID 39218876›Full record

ArticleJournal of nanobiotechnology2024

Temporal and spatial resolution of magnetosome degradation at the subcellular level in a 3D lung carcinoma model.

Alicia G Gubieda, Lucía Gandarias, Mihály Pósfai, Ajith Pattammattel, M Luisa Fdez-Gubieda, Ana Abad-Díaz-de-Cerio, Ana García-Prieto

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alicia G GubiedaDepartment of Immunology, Microbiology and Parasitology, University of the Basque Country (UPV/EHU), Leioa, 48940, Spain. alicia.gascon@ehu.eus.
Lucía GandariasDepartment of Immunology, Microbiology and Parasitology, University of the Basque Country (UPV/EHU), Leioa, 48940, Spain.
Mihály PósfaiResearch Center of Biomolecular and Chemical Engineering, University of Pannonia Veszprém, Veszprém, Hungary.
Ajith PattammattelNational Synchrotron Light Source II, Brookhaven National Laboratory, Upton, NY, 11973, USA.
M Luisa Fdez-GubiedaDepartment of Electricity and Electronics, University of the Basque Country (UPV/EHU), Leioa, 48940, Spain.
Ana Abad-Díaz-de-CerioDepartment of Immunology, Microbiology and Parasitology, University of the Basque Country (UPV/EHU), Leioa, 48940, Spain. ana.abad@ehu.eus.
Ana García-PrietoDepartment of Applied Physics, University of the Basque Country (UPV/EHU), Bilbao, 48013, Spain. ana.garciap@ehu.eus.

Funding

Eusko Jaurlaritza IT1479-22Hungarian National Research, Development and Innovation Office (NKFIH) RRF-2.3.1-21-2022-00014MCIN/AEI/10.13039/501100011033 PID2020-115704RB-C31
6 · The paper itself

Abstract

Magnetic nanoparticles offer many exciting possibilities in biomedicine, from cell imaging to cancer treatment. One of the currently researched nanoparticles are magnetosomes, magnetite nanoparticles of high chemical purity synthesized by magnetotactic bacteria. Despite their therapeutic potential, very little is known about their degradation in human cells, and even less so of their degradation within tumours. In an effort to explore the potential of magnetosomes for cancer treatment, we have explored their degradation process in a 3D human lung carcinoma model at the subcellular level and with nanometre scale resolution. We have used state of the art hard X-ray probes (nano-XANES and nano-XRF), which allow for identification of distinct iron phases in each region of the cell. Our results reveal the progression of magnetite oxidation to maghemite within magnetosomes, and the biosynthesis of magnetite and ferrihydrite by ferritin.

Indexed as

Ferrosoferric OxideLung NeoplasmsMagnetite NanoparticlesMagnetosomesCell Line, TumorFerric CompoundsFerritinsHumansOxidation-ReductionFerric Compoundsferric oxideFerritinsFerrosoferric OxideMagnetite NanoparticlesBiomineralisationFerritinMagnetic nanoparticle degradationMagnetosomeNano-XANESNano-XRF

Identifiers

PMID39218876
PMCPMC11367995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.